Independent 5-year pharmaceutical and healthcare industry forecasts for Lebanon.
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Lebanese pharmaceutical and healthcare industry.
Competitive intelligence, Lebanese pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Lebanese market.
The Lebanon Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to 2011 covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Its Lebanon Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Lebanese pharmaceutical and healthcare industry.
Key Benefits of Report
Benchmark Its Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Lebanon to test other views – a key input for successful budgeting and strategic business planning in the Lebanese pharmaceutical and healthcare market.
Target Business Opportunities & Risks in the Lebanese Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Lebanon.
Exploit The Latest Competitive Lebanese Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Lebanon.
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect Its forecast analysis, and taken together with Its Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
It 5-Year Industry Forecast
5-Year Forecasts to end-2011 for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism;
OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
Generics market (US$bn)/ as % of total market
Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke It economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
It 5-Year Macroeconomic Forecasts
It forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. It profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
Executive Summary
The Sector At A Glance
Key Insights On The Pharmaceutical Sector Of Lebanon
The Lebanese pharmaceutical market has shown solid growth in recent years, with annual expansion of 6- 7%, although this positive trend has been interrupted by the recent conflict. Particularly damaging has been the Israeli blockade, considering that Lebanon is reliant on imports for around 95% of pharmaceutical consumption. Prescription drugs dominate the market, with OTC drugs accounting for approximately 10% of the market. Generic drugs take only a small market share due to a lack of awareness of their merits among both consumers and health professionals.
It forecasts that the Lebanese drug market will be worth US$612.5mn at retail prices by 2010. Percapita drug expenditure is expected to reach US$154.4 in 2010. Drug prices in the country remain relatively high by regional standards. However, the government is said to be considering implementing a new pricing system, which would be based on the reference prices of drugs in similar markets around the world. This is unlikely to encourage multinational sector investment, but will enhance public access to medicines. Only about 62% of Lebanese have health insurance – either public or private – to help cover their drug costs.
Its adjusted Business Environment Rankings for the Middle East reveal that Lebanon is in the joint 10th place with Egypt, ahead only of Iran, Nigeria and Zimbabwe. This is primarily due to a number of regulatory barriers such as lax intellectual property (IP) standards. Lebanon’s uncertain long-term political and economic climate also has a negative impact on the country’s business environment rankings. The pharmaceutical market is set to be severely impacted by the conflict between Israel and Hizbollah. Exports and imports suffered severely across all industry sectors due to the Israeli blockade of ports and airports, which lasted from July to September 2006. Meanwhile, a fall in purchasing power will affect drug market sales.
In the future, Lebanon will have to tighten its IP regime if it wishes to attract greater foreign direct investment (FDI), and help its local industry to develop. Currently, the IP regime falls short of international standards, particularly in areas such as data exclusivity and pipeline protection. Counterfeiting is also rife, severely impacting sales for multinational companies. As a result, these are more likely to raise prices, in order to recoup losses, or economise in other areas such as R&D.
For more information, Please visit :
http://www.bharatbook.com/
